Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Addiction; neurology

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

Mouse studies suggest omigapil and other inhibitors of GAPDH nitrosylation could help treat cocaine addiction or overdose. In mice, omigapil decreased cocaine-mediated neurotoxicity compared with no treatment. In mice, omigapil decreased cocaine-induced hyperactivity and cocaine-seeking behavior compared with saline. Ongoing studies at the National Institute on Drug Abuse include evaluating the anticocaine effects of omigapil in animal models.
Santhera Pharmaceuticals Holding AG's omigapil, a selegiline derivative that targets GAPDH, is in Phase I testing to treat muscular dystrophy.

SciBX 6(24); doi:10.1038/scibx.2013.605
Published online June 20, 2013

Patented; available for licensing

Xu, R. et al. Neuron; published online May 22, 2013;
doi:10.1016/j.neuron.2013.03.021
Contact: Nilkantha Sen, The Johns Hopkins University School of Medicine, Baltimore, Md.
e-mail:

nsen@gru.edu
Contact: Solomon H. Snyder, same affiliation as above
e-mail:

ssnyder@jhmi.edu